TE Connectivity Opens 1st Global Medical Device Prototyping Center

TE Connectivity Corporation, a world leader in connectors and sensors, has opened its global Propelus Prototype Center for medical devices at its existing manufacturing site in Galway, Ireland.

The $5 million rapid prototyping center directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices.

With more than 120 patients treated every minute with a medical device containing TE Connectivity technology, TE’s Galway site fulfills close to the complete global demand for minimally invasive catheter metal shafts, such as coronary stents used to open clogged heart arteries and neurovascular coils which are used in the treatment of brain aneurysms.

The Propelus Prototype Center features advanced engineering capabilities, including build-to-print services, quick turnaround prototype production and 3D printing. TE engineers work alongside customers to quickly make customer concepts a reality, enabling them to visit and leave with a physical, functional prototype, along with a detailed commercialization proposal. TE Connectivity can also manufacture the customer’s final device at high volumes in one of TE’s global manufacturing facilities and help manage their supply chain.

Commenting on the launch of the Propelus Prototype Center, Director of Operations Mark Gill said: “The principle is simple – getting high quality prototypes into customers’ hands as quickly as possible. By improving the speed of product development and manufacturing, TE will help customers innovate and iterate advanced treatments at a more efficient pace, ultimately transforming patient care for the better.”

“When our Propelus Prototype Center engineers are not busy working on customer projects, they are innovating for the future, staying close to new therapies, and trialing new technologies so we stay ahead of the curve, today and tomorrow.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”